AAAAAA
Results:
1-11
|
Results: 11
Authors:
Faivre, S
Raymond, E
Boige, V
Gatineau, M
Buthaut, X
Rixe, O
Bernareggi, A
Camboni, G
Armand, JP
Citation: S. Faivre et al., A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies, CLIN CANC R, 7(1), 2001, pp. 43-50
Authors:
Rixe, O
Citation: O. Rixe, Concomitant radiochemotherapy for non-small-cell lung cancer: towards an ideal strategy, REV MAL RES, 18(4), 2001, pp. 365-366
Authors:
Becouarn, Y
Gamelin, E
Coudert, B
Negrier, S
Pierga, JY
Raoul, JL
Provencal, J
Rixe, O
Krisch, C
Germa, C
Bekradda, M
Mignard, D
Mousseau, M
Citation: Y. Becouarn et al., Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients, J CL ONCOL, 19(22), 2001, pp. 4195-4201
Authors:
Kissel, A
Rixe, O
Methlin, A
Nabet, M
Tranquart, F
Rubini, B
Jafaar, S
Gaucher, H
Citation: A. Kissel et al., Quantification of hepatic arterial and portal venous flow using US contrast agents for early detection of liver metastases from colon carcinoma, J RADIOLOG, 82(11), 2001, pp. 1621-1625
Authors:
Zelek, L
Barthier, S
Riofrio, M
Fizazi, K
Rixe, O
Delord, JP
Le Cesne, A
Spielmann, M
Citation: L. Zelek et al., Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma, CANCER, 92(9), 2001, pp. 2267-2272
Authors:
Vandier, D
Calvez, V
Massade, L
Gouyette, A
Mickley, L
Fojo, T
Rixe, O
Citation: D. Vandier et al., Transactivation of the metallothionein promoter in cisplatin-resistant cancer cells: a specific gene therapy strategy, J NAT CANC, 92(8), 2000, pp. 642-647
Authors:
Vandier, D
Rixe, O
Besnard, F
Kim, M
Rikiyama, T
Goldsmith, M
Brenner, M
Gouyette, A
Cowan, KH
Citation: D. Vandier et al., Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter, CANC GENE T, 7(8), 2000, pp. 1120-1126
Authors:
Delord, JP
Raymond, E
Chaouche, M
Ruffie, P
Ducreux, M
Faivre, S
Boige, V
Le Chevalier, T
Rixe, O
Baudin, E
Pautier, P
Rodier, JM
Chouaki, N
Escudier, B
Kayitalire, L
Armand, JP
Citation: Jp. Delord et al., A dose-finding study of gemcitabine and vinorelbine in advanced previouslytreated malignancies, ANN ONCOL, 11(1), 2000, pp. 73-79
Authors:
Boige, V
Raymond, E
Faivre, S
Gatineau, M
Meely, K
Mekhaldi, S
Pautier, P
Ducreux, M
Rixe, O
Armand, JP
Citation: V. Boige et al., Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer, J CL ONCOL, 18(23), 2000, pp. 3986-3992
Authors:
Rixe, O
Citation: O. Rixe, Platinum compounds: mechanisms of action, mechanisms of cellular resistance in human cancers, interactions with ionising radiations, application to carboplatin, B CANCER, 87, 2000, pp. 7-15
Authors:
Spielmann, M
Llombart, A
Zelek, L
Sverdlin, R
Rixe, O
Le Cesne, A
Citation: M. Spielmann et al., Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer, ANN ONCOL, 10(12), 1999, pp. 1457-1460
Risultati:
1-11
|